Our R&D

PIPELINE

We’re expanding what’s possible with cell therapy.

We are developing a wholly-owned pipeline of advanced cell therapies with the potential to redefine standards of care across a range of diseases where there is an urgent medical need. Explore our pipeline below for information on our clinical development candidates and ongoing clinical trials.

  • CANDIDATE
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
  • PHASE 3

Omidubicel

High-risk Hematologic Malignancies
Read More
PHASE 3
Severe Aplastic Anemia
Read More
PHASE 1

GDA-201

Non-Hodgkin Lymphoma, Multiple Myeloma
Read More
PHASE 1

PLATFORM

Cell-based therapies are recognized for their tremendous potential to provide curative treatment options for patients with blood cancers and rare, serious blood disorders. However, efforts to create effective treatments to date have been hampered by the inability to expand cells in the laboratory while maintaining therapeutic functionality.

At Gamida Cell, we’re pioneering a new approach with the potential to improve treatment outcomes beyond what is possible with donor-derived therapies. Our proprietary platform allows us to expand multiple cell types — including stem cells and natural killer (NK) cells — while maintaining their original phenotype and potency. This approach enables us to administer a therapeutic dose of cells to patients.

Selected Publications and Presentations

2019

Phase 1 Data on GDA-201 Presented at ASH

Results of a Phase 1 Trial of GDA-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Presented at the 2019 ASH Annual Meeting.

NAM Mechanism of Action Data Presented at ASH

Nicotinamide (NAM) Modulates Transcriptional Signature of Ex Vivo Cultured UCB CD34+ Cells (Omidubicel) and Preserves Their Stemness and Engraftment Potential

Presented at the 2019 ASH Annual Meeting.

Phase 1/2 Translational Data on Omidubicel Presented at TCT

Rapid and Robust CD4+ and CD8+ T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation.

Presented at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR).

Phase 1 GDA-201 Data Presented at TCT

First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer Cells for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

Presented at the 2019 TCT Meetings of ASBMT and CIBMTR.

Initial Phase 1/2 Data on Omidubicel in Aplastic Anemia Presented at TCT

Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Blood (UCB) Transplantation for Refractory Severe Aplastic Anemia Results in Rapid Engraftment and Expedites Immune Recovery

Presented at the 2019 TCT Meetings of ASBMT and CIBMTR.

Phase 1/2 Data on Omidubicel Published in JCO

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo with Nicotinamide

Journal of Clinical Oncology 2019 Feb 10;37(5):367-374.

2018

Phase 1 Data on GDA-201 Presented at AACR

Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer (NK) Cells for the Treatment of Relapsed/Refractory CD20+ non-Hodgkin Lymphoma

Presented at the 2018 International Meeting on Advances in Malignant Lymphoma.

2017

ASH Presentation on Cell-Expansion Platform for NK Cells

Presented at the 2017 ASH Annual Meeting.

Phase 1/2 Omidubicel Data Presented at ASH

NiCord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/ II Trial

Presented at the 2017 ASH Annual Meeting.

Omidubicel Clinical Outcomes Data Published in BBMT

Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization

Biol Blood Marrow Transplant. 2017 Jul;23(7):1151-1157.